News about Global Pharma

Lundbeck to Acquire Longboard Pharmaceuticals to Expand its Neuroscience Pipeline

Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Longboard common stock, whereby Longboard shareholders will be offered a payment of USD 60.00 per share in cash.

Global Pharma | 15/10/2024 | By Aishwarya |  898

RedHill Biopharma Bags Funding Through BARDA to Advance Opaganib for Ebola Treatment

Under this cost-sharing contract, BARDA will provide partial funding for the company to further advance opaganib to mitigate infection and contain EBOV outbreaks.

Global Pharma | 15/10/2024 | By Aishwarya |  714

Akeso Receives USD 250 Million to Boost Global Expansion of its Drug Pipeline

Seventy percent of the financing will accelerate the global clinical development of innovative drugs developed internally by Akeso, with a primary focus on its core products in both China and international markets.

Global Pharma | 14/10/2024 | By Aishwarya |  869

NRA Meets WHO International Standards for Vaccine Regulations

WHO has established global standards and benchmarks for assurance of vaccine quality through the development of tools and guidelines, benchmarking of the NRA and prequalification programme of vaccines.

Global Pharma | 14/10/2024 | By Aishwarya |  785

Orasis Pharmaceuticals Bags USD 78 Million in Series D Financing

Concurrent with its equity raise, Orasis has secured USD 15 million in structured capital from Catalio Capital Management, of which USD 10 million will be drawn at closing.

Global Pharma | 11/10/2024 | By Aishwarya |  665

Indegene to Host Sixth Edition of Indegene Digital Summit for Pharma Leaders

This year’s edition offers practitioners' perspectives on key topics such as Generative AI, Advanced Analytics, Technology Transformation and Operations Transformation.

Global Pharma | 11/10/2024 | By Aishwarya |  563

GSK Announces Positive Data for Arexvy (RSV) Vaccine

Arexvy is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older, including those who are at increased risk due to certain underlying medical conditions.

Global Pharma | 10/10/2024 | By Aishwarya |  811

Aptar Pharma Acquires Device Technology Assets of SipNose

SipNose offers a variety of devices that are designed and adapted to fit a wide range of therapies and offer the opportunity to precisely target areas of the nasal cavity to enable enhanced systemic, local or even direct-to-brain delivery.

Global Pharma | 10/10/2024 | By Aishwarya |  551

Mankind Pharma Bags CCI Approval for BSV Acquisition

The proposed transaction involves the acquisition of 100 percent shareholding of Bharat Serums and Vaccines Ltd. (BSV) by Mankind Pharma Ltd.

Global Pharma | 10/10/2024 | By Aishwarya |  811

Biocon Biologics' Report Offers Insights on Increasing Biosimilars Adoption in LMICs

Biocon Biologics commissioned the study, defined the methodology and collaborated with Clarivate to develop the final report.

Global Pharma | 09/10/2024 | By Aishwarya |  636